Abstract 1245P
Background
Specific requirements of the minimum number of harvested lymph nodes for accurate nodal staging in small intestinal tumors are sparse as there is a probability that false-negative lymph nodes remain. The aim of this study is to establish a histologic-type-specific nodal staging score (NSS) model for the specific requirements of lymph nodes in small intestinal tumors by taking potential false-negative lymph nodes into consideration.
Methods
Small intestinal tumors with complete follow-up and examined/positive lymph nodes data were retrieved using the Surveillance, Epidemiology, and End Results program. Using a beta-binomial model, the probability of lymph nodes with occult disease and the NSS model were established.
Results
A total of 7649 small intestinal tumors were retrieved, including 3789 carcinoid cases, 2467 adenocarcinoma cases, 718 neuroendocrine carcinoma cases, 502 sarcoma cases, and 173 others. To reach a 0.05 false-negative probability, the minimum number of lymph nodes was 10 in carcinoid tumors, 11 in adenocarcinoma, 12 in neuroendocrine carcinoma, 7 in sarcoma, and 16 in others. Distinct NSS curves were presented among each histologic type of small intestinal tumors. The NSS of neuroendocrine carcinoma indicated that a higher number of lymph nodes was required to enable the correct staging of lymph nodes compared to other types of small intestinal tumors. The prognostic values of NSS quartiles were validated.
Conclusions
The minimum required number of examined lymph nodes varied in each histologic type of small intestinal tumors. The NSS improved the adequacy of nodal staging for patients for clinical interpretation and decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1229P - Selective phenotypic and genotypic evaluation of circulating glial cells for improved diagnosis of glial malignancies
Presenter: Sewanti Limaye
Session: Poster session 14
1230P - hPG80 (circulating progastrin) is a new blood-based biomarker for diagnosis of early-stage non-small cell lung cancers
Presenter: Paul Hofman
Session: Poster session 14
1231P - Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer
Presenter: Yeji Jung
Session: Poster session 14
1232P - Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification
Presenter: Xinrong Yang
Session: Poster session 14
1233P - Accurate prediction of gastrointestinal cancer tissue of origin using comprehensive plasma cell-free DNA fragmentomics features
Presenter: Xinrong Yang
Session: Poster session 14
1234P - HistoMate: Automated preprocessing software for digital histopathology image to enhance deep learning
Presenter: Jinok Lee
Session: Poster session 14
1235P - Enrichment of rare cancers in pragmatic precision cancer medicine trial: Experience from IMPRESS-Norway
Presenter: Aaslaug Helland
Session: Poster session 14
1236P - Feasibility of online symptom monitoring to detect lung cancer relapse in Poland
Presenter: Ewa Pawlowska
Session: Poster session 14
1237P - Design and validation of a custom next-generation sequencing panel in melanoma, glioma and gastrointestinal stromal tumor
Presenter: Xiaoyan Zhou
Session: Poster session 14
1238P - Detecting driver mutations by AmoyDx 11-gene PCR with high concordance with next-generation sequencing in Chinese non-small cell lung cancer patients
Presenter: Dongmei Lin
Session: Poster session 14